학술논문

Deamidation-related blood biomarkers show promise for early diagnostics of neurodegeneration
Document Type
article
Source
Biomarker Research, Vol 10, Iss 1, Pp 1-10 (2022)
Subject
Neurodegenerative diseases (NDDs)
Early diagnosis
Blood biomarker
Deamidation
Isoaspartate
Human serum albumin (HSA)
Therapeutics. Pharmacology
RM1-950
Language
English
ISSN
2050-7771
Abstract
Abstract Background The strongest risk factor of neurodegenerative diseases (NDDs) is aging. Spontaneous asparaginyl deamidation leading to formation of isoaspartate (isoAsp) has been correlated with protein aggregation in NDDs. Methods Two cohorts consisting of 140 subjects were studied. Cohort 1 contained patients with AD and healthy controls, while Cohort 2 recruited subjects with mild cognitive impairment (MCI), vascular dementia (VaD), frontotemporal dementia (FTD), Parkinson’s disease (PD) and healthy controls. The levels of isoAsp in plasma human albumin (HSA), the most abundant protein in plasma, as well as the levels of immunoglobulin G (IgG) specific against deamidated HSA were measured. Apart from the memory tests, plasma biomarkers for NDDs reported in literature were also quantified, including amyloid beta (Aβ) peptides Aβ40 and Aβ42, neurofilament light protein (NfL), glial fibrillary acidic protein (GFAP) and phosphorylated tau 181 (p-tau181) protein. Results Deamidation products of blood albumin were significantly elevated in vascular dementia and frontotemporal dementia (P